Retrospective and Prospective Study on Professional Continuous Glucose Monitoring in Insulin-treated Type 2 Diabetes

NACompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

March 22, 2015

Primary Completion Date

January 24, 2017

Study Completion Date

March 1, 2018

Conditions
Diabetes Mellitus, Type 2
Interventions
DEVICE

Continuous Glucose Monitoring (CGM)

"On each visit (baseline, 4, 8, and 12 months), participants received an iPro2 CGM device (MiniMed Medtronic), placed according to the manufacturer's standard procedure. The iPro2 was used each time for 7-days. During this period, patients were asked to perform 4 SMBG measurements daily for calibration (fasting, lunch, dinner, and before bed). Patients received a diary to register food intake, physical activity and medication, SMBG values, and any diabetes-related event (extra consultations, phone calls, etc) in the previous 4 months.~Each time, CGM data was interpreted by an expert clinician, and a report was delivered, within one week, to the respective healthcare team. This report was discussed together by the patient and one member of the healthcare team, either in consultation or by phone, agreeing on any necessary therapeutic changes. If necessary, extra consultations for nutrition, nursing, or education, were scheduled, to address specific needs identified during rCGM review."

Trial Locations (1)

1250-189 Lisboa

APDP, Lisbon

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Medtronic

INDUSTRY

lead

Associacao Protectora dos Diabeticos de Portugal

OTHER